• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.

作者信息

Kuhnl Andrea, Roddie Claire, Kirkwood Amy A, Menne Tobias, Cuadrado Maria, Marzolini Maria A V, Osborne Wendy, Sanderson Robin, O'Reilly Maeve, Townsend William, Benjamin Reuben, Potter Victoria, Patten Piers E M, Yallop Deborah, Voo Stefan, Petrides George S, Mulholland Nicola, Kayani Irfan

机构信息

Department of Haematology, King's College Hospital, London, UK.

Department of Haematology, University College London Hospital, London, UK.

出版信息

Blood Adv. 2022 Jan 11;6(1):321-326. doi: 10.1182/bloodadvances.2021005807.

DOI:10.1182/bloodadvances.2021005807
PMID:34700342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8753214/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/8753214/ecf62669062f/advancesADV2021005807f1ab.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/8753214/a8a0b32d8848/advancesADV2021005807absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/8753214/ecf62669062f/advancesADV2021005807f1ab.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/8753214/a8a0b32d8848/advancesADV2021005807absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/8753214/ecf62669062f/advancesADV2021005807f1ab.jpg

相似文献

1
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.早期氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）反应可预测大B细胞淋巴瘤的嵌合抗原受体T细胞（CAR-T）治疗失败。
Blood Adv. 2022 Jan 11;6(1):321-326. doi: 10.1182/bloodadvances.2021005807.
2
2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS.2-[18F]氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描用于评估1例患有免疫效应细胞相关神经毒性综合征的弥漫性大B细胞淋巴瘤患者接受嵌合抗原受体T细胞治疗后的早期反应和脑代谢模式
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1090-1091. doi: 10.1007/s00259-021-05562-2. Epub 2021 Sep 22.
3
Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.氟-18-氟脱氧葡萄糖正电子发射断层扫描在弥漫性大B细胞淋巴瘤中的应用
PET Clin. 2014 Oct;9(4):443-55, vi. doi: 10.1016/j.cpet.2014.06.001. Epub 2014 Jul 30.
4
[The outcome of whole-body FDG-PET examination predicts the future of patients with diffuse large-cell lymphoma--editorial].[全身氟代脱氧葡萄糖正电子发射断层扫描检查结果可预测弥漫性大细胞淋巴瘤患者的预后——编者按]
Vnitr Lek. 2007 Sep;53(9):918.
5
Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion.嵌合抗原受体T细胞（CAR-T）输注后15天，[18F]氟代脱氧葡萄糖正电子发射断层扫描（PET-CT）上观察到淋巴瘤假性进展。
Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2447-2449. doi: 10.1007/s00259-022-05722-y. Epub 2022 Feb 11.
6
An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.弥漫性大 B 细胞淋巴瘤和霍奇金淋巴瘤患者中氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）中期再分期作用的更新。
J Natl Compr Canc Netw. 2010 Mar;8(3):347-52. doi: 10.6004/jnccn.2010.0023.
7
The role of FDG-PET in the interim evaluation of therapy response in diffuse large B-cell lymphoma.氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）在弥漫性大B细胞淋巴瘤治疗反应中期评估中的作用
Transfus Apher Sci. 2013 Aug;49(1):40-2. doi: 10.1016/j.transci.2013.05.023. Epub 2013 Jun 14.
8
Bilateral cutaneous diffuse large B-cell lymphoma on FDG PET/CT.基于氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）的双侧皮肤弥漫性大B细胞淋巴瘤
Clin Nucl Med. 2011 Oct;36(10):e153-5. doi: 10.1097/RLU.0b013e31821c9a7d.
9
A rare case of Diffuse Large B-Cell Lymphoma of the Prostate on 18F-FDG PET-CT.18F-FDG PET-CT 显像前列腺弥漫大 B 细胞淋巴瘤 1 例罕见报告
J Pak Med Assoc. 2021 Jan;71(1(B)):388-389.
10
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.弥漫性大B细胞淋巴瘤患者化疗期间通过（18）氟代脱氧葡萄糖正电子发射断层扫描进行早期治疗反应评估：孤立的骨残留阳性通常不是后续治疗失败的预测指标。
Leuk Lymphoma. 2007 Mar;48(3):596-600. doi: 10.1080/10428190601099965.

引用本文的文献

1
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma.大B细胞淋巴瘤中CD19嵌合抗原受体T细胞疗法的国际代谢预后指数的优化与验证
Blood Cancer J. 2025 Aug 26;15(1):144. doi: 10.1038/s41408-025-01338-1.
2
Noncanonical and mortality-defining toxicities of CAR T cell therapy.嵌合抗原受体T细胞疗法的非典型及决定死亡率的毒性作用
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
3
[F]FDG-PET/CT in DLBCL-patients treated with CAR-T cell therapy: potential for defining patient prognosis.

本文引用的文献

1
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.循环肿瘤DNA监测可改善大B细胞淋巴瘤患者接受阿基仑赛注射液输注后的早期复发检测：一项前瞻性多机构试验的结果
J Clin Oncol. 2021 Sep 20;39(27):3034-3043. doi: 10.1200/JCO.21.00377. Epub 2021 Jun 16.
2
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.抗 CD19 嵌合抗原受体 T 细胞治疗侵袭性 B 细胞淋巴瘤患者中 18F-FDG PET/CT 的预后影响。
Clin Nucl Med. 2021 Aug 1;46(8):627-634. doi: 10.1097/RLU.0000000000003756.
3
[F]接受嵌合抗原受体T细胞（CAR-T）疗法治疗的弥漫性大B细胞淋巴瘤（DLBCL）患者的氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）：用于定义患者预后的潜力
Eur J Radiol Open. 2025 Jun 5;14:100663. doi: 10.1016/j.ejro.2025.100663. eCollection 2025 Jun.
4
Prognostic value of early post-treatment F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy.接受嵌合抗原受体T细胞疗法的弥漫性大B细胞淋巴瘤患者治疗后早期F-FDG PET/CT的预后价值
Cancer Imaging. 2025 Jun 8;25(1):70. doi: 10.1186/s40644-025-00888-8.
5
Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.半定量PET参数改善CAR-T治疗淋巴瘤1个月和3个月后的预后：一项前瞻性单中心研究
J Nucl Med. 2025 Apr 17. doi: 10.2967/jnumed.125.269670.
6
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.非霍奇金淋巴瘤中对CAR-T细胞疗法反应的炎症生物标志物特征
Nat Med. 2025 Apr;31(4):1183-1194. doi: 10.1038/s41591-025-03532-x. Epub 2025 Apr 1.
7
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma.肝脏对氟代脱氧葡萄糖（FDG）的摄取增强了正电子发射断层扫描/计算机断层扫描（PET/CT）对弥漫性大B细胞淋巴瘤中靶向CD19的嵌合抗原受体T细胞（CAR-T）疗法的早期预后价值。
EJNMMI Res. 2025 Mar 17;15(1):25. doi: 10.1186/s13550-025-01201-1.
8
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.获批的针对大B细胞淋巴瘤的CD19靶向嵌合抗原受体T细胞的疗效相关因素。
Nat Rev Clin Oncol. 2025 Apr;22(4):241-261. doi: 10.1038/s41571-025-00992-5. Epub 2025 Feb 18.
9
Biomarkers of outcome in patients undergoing CD19 CAR-T therapy for large B cell lymphoma.接受CD19嵌合抗原受体T细胞（CAR-T）疗法治疗的大B细胞淋巴瘤患者的预后生物标志物。
Hemasphere. 2024 Aug 22;8(8):e130. doi: 10.1002/hem3.130. eCollection 2024 Aug.
10
Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities.淋巴瘤患者的长轴向视野 PET 成像：挑战与机遇。
PET Clin. 2024 Oct;19(4):495-504. doi: 10.1016/j.cpet.2024.05.005. Epub 2024 Jul 4.
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
弥漫性大 B 细胞淋巴瘤中 PET 中期评估的最佳时机和标准：一项 1692 例患者的对比研究。
Blood Adv. 2021 May 11;5(9):2375-2384. doi: 10.1182/bloodadvances.2021004467.
4
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.奥滨尤妥珠单抗对比利妥昔单抗用于晚期弥漫性大 B 细胞淋巴瘤：LYSA 的一项基于 PET 指导的随机 3 期研究。
Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750.
5
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.复发/难治性弥漫性大B细胞淋巴瘤患者接受CAR T细胞治疗后早期进展的预测因素
Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001.
6
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.肿瘤负荷、炎症和产品属性决定了阿基仑赛注射液治疗大B细胞淋巴瘤的疗效。
Blood Adv. 2020 Oct 13;4(19):4898-4911. doi: 10.1182/bloodadvances.2020002394.
7
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.阿基卡宾赛妥昔单抗在非临床试验环境下的疗效、耐药性和毒性的结果和相关性。
J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15.
8
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.阿基仑赛用于复发或难治性大 B 细胞淋巴瘤的标准治疗：来自美国淋巴瘤嵌合抗原受体 T 细胞治疗联盟的结果。
J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13.
9
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.弥漫性大 B 细胞淋巴瘤中中间 FDG-PET 的预后价值：CALGB 50303 临床试验结果。
Blood. 2020 Jun 18;135(25):2224-2234. doi: 10.1182/blood.2019003277.
10
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.